Adsorption of acellular DTP, recombinant hepatitis B, and Haemophilus influenzae type b combined vaccine (Walvax Biotechnology)
吸附无细胞百白破、重组乙型肝炎、b型流感嗜血杆菌联合疫苗（沃森生物）
Report date: 2022/01/14 13:23:58
Base Information
Drug NameAdsorption of acellular DTP, recombinant hepatitis B, and Haemophilus influenzae type b combined vaccine (Walvax Biotechnology)
Drug Alias NameN/A
Classification
Mechanisms of Action
Targets
Therapy Area/Indications +[5]
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesYuxi Walvax Biotechnology Co Ltd
China Registration ClassN/A
Develop Information
Active CompaniesWalvax Biotechnology Co Ltd
Inactive CompaniesN/A
Active Indications +[5]
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A